Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu-Pei Wu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Molecular Pharmaceutics|December 25, 2012
Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptideShu-Pei Wu, David E Smith
Molecular Pharmaceutics|July 12, 2018
Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active UptakeParesh P Chothe, Shu-Pei Wu, Zhengqi Ye, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2014
The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brainRamola Sane, Shu-Pei Wu, Rong Zhang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout miceDilara Jappar, Shu-Pei Wu, Yongjun Hu, et al.
Journal of Food and Drug Analysis|October 9, 2017
Enhanced active extracellular polysaccharide production from Ganoderma formosanum using computational modelingKai-Di Hsu, Shu-Pei Wu, Shin-Ping Lin, et al.
Epilepsia|March 11, 2004
Interaction between anticonvulsants and human placental carnitine transporterShu-Pei Wu, Ming-Kwang Shyu, Horng-Huei Liou, et al.
Pulmonary Therapy|August 1, 2020
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/IvacaftorAlice Tsai, Shu-Pei Wu, Eric Haseltine, et al.
Pulmonary Therapy|August 29, 2020
Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/IvacaftorAlice Tsai, Shu-Pei Wu, Eric Haseltine, et al.
Molecular Pharmaceutics|April 26, 2026
Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded AntibodiesTam N T Nguyen, Philip K-Y Chang, Paul Panorchan, et al.
Scientific Reports|September 10, 2016
Extract of Ganoderma formosanum Mycelium as a Highly Potent Tyrosinase InhibitorKai-Di Hsu, Hong-Jhang Chen, Chi-Shin Wang, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Pharmaceutics|December 25, 2012
Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptideShu-Pei Wu, David E Smith
Molecular Pharmaceutics|July 12, 2018
Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active UptakeParesh P Chothe, Shu-Pei Wu, Zhengqi Ye, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2014
The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brainRamola Sane, Shu-Pei Wu, Rong Zhang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout miceDilara Jappar, Shu-Pei Wu, Yongjun Hu, et al.
Journal of Food and Drug Analysis|October 9, 2017
Enhanced active extracellular polysaccharide production from Ganoderma formosanum using computational modelingKai-Di Hsu, Shu-Pei Wu, Shin-Ping Lin, et al.
Epilepsia|March 11, 2004
Interaction between anticonvulsants and human placental carnitine transporterShu-Pei Wu, Ming-Kwang Shyu, Horng-Huei Liou, et al.
Pulmonary Therapy|August 1, 2020
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/IvacaftorAlice Tsai, Shu-Pei Wu, Eric Haseltine, et al.
Pulmonary Therapy|August 29, 2020
Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/IvacaftorAlice Tsai, Shu-Pei Wu, Eric Haseltine, et al.
Molecular Pharmaceutics|April 26, 2026
Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded AntibodiesTam N T Nguyen, Philip K-Y Chang, Paul Panorchan, et al.
Scientific Reports|September 10, 2016
Extract of Ganoderma formosanum Mycelium as a Highly Potent Tyrosinase InhibitorKai-Di Hsu, Hong-Jhang Chen, Chi-Shin Wang, et al.
Pageof 2